The patients were randomized into the training and validation cohorts at a ratio of 2:1, using the “rms” package in R. The nomogram showed that the EGFR mutation status and Ki-67 had the most significant contribution to OS in NSCLC. This evidence concerns the gene MKI67 and non-small cell lung carcinoma.